Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: Results from the nationwide Swedish register

Rheumatology (United Kingdom)

Volumn 58, Issue 8, 2019, Pages 1367-1377

  Frisell, Thomas ^a   Dehlin, Mats ^b   Di Giuseppe, Daniela ^a   Feltelius, Nils ^c   Turesson, Carl ^d,e   Askling, Johan ^a   Ernestam, Sofia ^f   Klareskog, Lars ^f   Nisell, Ralph ^f   Baecklund, Eva ^f   Kastbom, Alf ^f   Jacobsson, Lennart ^f   Lindqvist, Elisabet ^f   D'Elia, Helena Forsblad ^f   Rantapää Dahlqvist, Solbritt ^f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f NONE

Author keywords

abatacept; anti TNF; biologics; effectiveness; rheumatoid arthritis; rituximab; tocilizumab; treatment outcome

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); PHARMACEUTICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SWEDEN; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85081607009     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/key433     Document Type: Article

References (41)

1. Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
2. Singh JA, Saag KG, Bridges SL Jr et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
3. Smolen JS, Landewe R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
4. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
5. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
6. Schiff M, Weinblatt ME, Valente R et al. Head-To-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86-94.
7. Manders SH, Kievit W, Adang E et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: A pragmatic multi-centre randomised trial. Arthritis Res Ther 2015;17:134.
8. Porter D, van Melckebeke J, Dale J et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): An open-label, randomised controlled, non-inferiority, trial. Lancet 2016;388:239-47.
9. Gottenberg JE, Brocq O, Perdriger A et al. Non-TNF-Targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug. A randomized clinical trial. JAMA 2016;316:1172-80.
10. Singh JA, Hossain A, Tanjong Ghogomu E et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional diseasemodifying anti-rheumatic drugs: A systematic review and network meta-Analysis. Cochrane Database Syst Rev 2016;5:CD012183.
11. Singh JA, Hossain A, Tanjong Ghogomu E et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: A systematic review and network meta-Analysis. Cochrane Database Syst Rev 2017;3:CD012591.
12. Finckh A, Ciurea A, Brulhart L et al. B cell depletion may be more effective than switching to an alternative anti-Tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-Tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
13. Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFalpha blocker failure. Biologics 2012;6:191-9.
14. Soliman MM, Hyrich KL, Lunt M et al. Rituximab or a second anti-Tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-Tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2012;64:1108-15.
15. Emery P, Gottenberg JE, Rubbert-Roth A et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: sWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 2015;74:979-84.
16. Harrold LR, Reed GW, Magner R et al. Comparative effectiveness and safety of rituximab versus subsequent anti-Tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-Tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther 2015;17:256.
17. Gomez-Reino JJ, Maneiro JR, Ruiz J et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study. Ann Rheum Dis 2012;71:1861-4.
18. Backhaus M, Kaufmann J, Richter C et al. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: A retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol 2015;34:673-81.
19. Iannone F, Ferraccioli G, Sinigaglia L et al. Real-world experience of tocilizumab in rheumatoid arthritis: subanalysis of data from the Italian biologics? register GISEA. Clin Rheumatol 2018;37:315-21.
20. Kihara M, Davies R, Kearsley-Fleet L et al. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: An observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clin Rheumatol 2017;36:241-50.
21. Lauper K, Nordstrom DC, Pavelka K et al. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: Analyses from the pan-European TOCERRA register collaboration. Ann Rheum Dis 2018;77:1276-82.
22. Romao VC, Santos MJ, Polido-Pereira J et al. Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients: data from the rheumatic diseases portuguese register, Reuma.pt. Biomed Res Int 2015;2015:279890.
23. Yoshida K, Tokuda Y, Oshikawa H et al. An observational studyof tocilizumabandTNF-Alphainhibitoruse ina Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology 2011;50:2093-9.
24. Jones G, Hall S, Bird P et al. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. Int J Rheum Dis 2018;21:1581-90.
25. Harrold LR, Reed GW, Kremer JM et al. The comparative effectiveness of abatacept versus anti-Tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-Tumour necrosis factor. Ann Rheum Dis 2015;74:430-6.
26. Askling J, Fored CM, Geborek P et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
27. Frisell T, Holmqvist M, Kallberg H et al. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum 2013;65:2773-82.
28. Eriksson JK, Askling J, Arkema EV. The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register-enriched data. Clin Exp Rheumatol 2014;32(5 Suppl 85):S-147-9.
29. Wadstrom H, Eriksson J, Neovius M, Askling J, on behalf of The Artis Study Group. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)? Scand J Rheumatol 2015;44:22-8.
30. Wettermark B, Hammar N, Fored CM et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35.
31. Socialstyrelsen. Inpatient diseases in Sweden 1987-2008. Stockholm, 2008 (in Swedish). https://www.socialstyrelsen. se/Lists/Artikelkatalog/Attachments/17782/2009-10-114.pdf.
32. Ludvigsson JF, Andersson E, Ekbom A et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
33. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: A sample survey for year 1998. Acta Oncol 2009;48:27-33.
34. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a fiveyear observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600-6.
35. Frisell T, Baecklund E, Bengtsson K et al. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Ann Rheum Dis 2018;77:650-7.
36. Cheung YB. A modified least-squares regression approach to the estimation of risk difference. Am J Epidemiol 2007;166:1337-44.
37. Neovius M, Arkema EV, Olsson H et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 2015;74:354-60.
38. Bergman GJD, Hochberg MC, Boers M et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39:425-41.
39. Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: A network meta-Analysis. J Manag Care Spec Pharm 2015;21:409-23.
40. Li T, Puhan MA, Vedula SS, Singh S, Dickersin K. Network meta-Analysis-highly attractive but more methodological research is needed. BMC Med 2011;9:79.
41. Iannone F, Ferraccioli G, Sinigaglia L et al. Real-world experience of tocilizumab in rheumatoid arthritis: subanalysis of data from the Italian biologics? register GISEA. Clin Rheumatol 2018;37:315-21.